●Identify types of immune checkpoint inhibitors and possible neuromuscular side effects of ICI therapy
●Define the severity of the ICI-related complications
●Differentiate ICI-induced neuromuscular conditions with other mimics
●Interpret lab abnormalities associated with ICI-induced neuromuscular conditions
●Apply appropriate treatment to patients with ICI-induced neuromuscular conditions
Session date: 
04/29/2024 - 4:00pm to 5:00pm CDT
Location: 
Virtually
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™
Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Yajing Ye, Neurology Resident